)
)
Xintela Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Xintela
Access all reports
Xintela AB is a Sweden-based biomedical company specializing in regenerative medicine and cancer treatments. The company focuses on developing therapies for cartilage damage and osteoarthritis using its proprietary XINMARK technology, which identifies specific stem cells that can develop into cartilage cells. In oncology, Xintela is working on targeted treatments for aggressive cancers, including glioblastoma. Through its subsidiary Targinta, the company also develops antibody-based therapies targeting cancer cells. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
XINT
Country
🇸🇪 Sweden